Abstract
Background and Objectives: Percutaneous mitral balloon valvuloplotomy (PMV) is a safe and effective procedure for the treatment of mitral stenosis (MS); however, its long-term results according to the severity of MS remain unknown. The aim of this study was to compare the long-term results of PMV between moderate and severe MS. Subjects and Methods: The immediate and long-term outcomes of 786 patients (198 male, mean age; 43 years) who underwent PMV at a single referral center, between 1988 and 2000, were analyzed. The clinical and echocardiographic data were compared between moderate (n=357) and severe MS (n=429). Results: Optimal results were gained in 618 (79%) patients, including 80 and 76% moderate and severe MS cases, respectively (p=0.13). Acute complications occurred in 85 patients (11%), but without significant difference between the two groups. After a mean follow-up period of 94 months (range, 6 to 210 month), the 5 year event-free survival rate was better in moderate (88%) than in severe MS (79%), but the 10 year event-free survival rates were no different (65% vs. 65%). Independent predictors for better prognosis were a lower echo score (≤8) (p=0.017, HR=0.67), a larger mitral valve area after the PMV (≥1.7 cm2) (p=0.002, HR=0.65), less mitral regurgitation (<grade III) (p=0.001, HR=0.46) and a lower left atrial pressure (<12 mmHg) (p=0.005, HR=0.80). Conclusion: The immediate and long-term outcomes of PMV for moderate MS were no better after 9 years than those for severe MS. Therefore, PMV for moderate MS should be considered in selected cases with a favorable MV morphology.
Original language | English |
---|---|
Pages (from-to) | 208-213 |
Number of pages | 6 |
Journal | Korean Circulation Journal |
Volume | 36 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2006 Mar |
Bibliographical note
Funding Information:The work was funded by Pathology Queensland, a Royal Brisbane and Women’s Hospital Research Grant, the Kidney Research Foundation, and National Health and Medical Research Council Project Grants (GNT1099222 and GNT1161319). Dr. Law was supported by a Pathology Queensland Study, Education, and Research Committee Scholarship. Mr. Giuliani was supported by an Australian Government Research Training Program Scholarship.
Funding Information:
A/Prof. Healy reports grants from the National Health and Medical Research Council (GNT1099222), grants from Royal Brisbane & Women’s Hospital Foundation (project grant), grants and other from Royal Brisbane & Women’s Hospital (institutional grant), and other from Chemical Pathology, Pathology Queensland, during the conduct of the study.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Cardiology and Cardiovascular Medicine